Literature DB >> 18383329

Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: clinical characteristics and association with soluble adhesion molecule expression.

Elizabeth S Klings1, Demedrick Anton Bland, Dara Rosenman, Stephanie Princeton, Adam Odhiambo, Guihua Li, Sheilah A Bernard, Martin H Steinberg, Harrison W Farber.   

Abstract

Pulmonary hypertension (PH), a risk factor for mortality in sickle cell disease (SCD), has pathologic features of both pulmonary arterial hypertension (PAH) and PH related to left-sided heart disease (LHD) suggesting a link between these two entities. We hypothesized that both are characterized by endothelial dysfunction and increased adhesion molecule expression. SCD patients and normal volunteers underwent a screening questionnaire, echocardiogram, and blood donation for preparation of platelet-poor plasma. PAH was defined as a tricuspid regurgitant jet (TRJ) velocity > or =2.5 m/sec and/or the presence of isolated right ventricular hypertrophy or decreased systolic function. LHD was defined as either left-sided systolic/diastolic dysfunction or significant valvular disease. Plasma vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), P- and E-selectin, nitric oxide (NO(x)), erythropoietin, and vascular endothelial growth factor (VEGF) levels were assayed by enzyme-linked immunoassay. Forty-three percent of sickle cell anemia (HbSS) and 28% of hemoglobin SC disease (HbSC) disease patients had PAH. Additionally, 10-15% of SCD patients had LHD. VCAM-1 levels were significantly increased in HbSS patients compared with HbSC patients and normal volunteers. VCAM-1 and P-selectin levels correlated positively with TRJ velocity in HbSS patients (r = 0.45, P = 0.03, r = 0.2, P = 0.05, respectively). ICAM-1, E-selectin, NO(x), erythropoietin, and VEGF levels were similar across subject groups. PH is common in SCD and, at times, due to LHD. Increased VCAM-1 and P-selectin expression was associated with TRJ elevation regardless of etiology suggesting a similar effect on endothelial gene expression and possibly providing a pathologic link between PAH and PH related to LHD in SCD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18383329     DOI: 10.1002/ajh.21187

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  22 in total

1.  Management of patients with sickle cell disease.

Authors:  Elizabeth S Klings; Gregory J Kato; Mark T Gladwin
Journal:  JAMA       Date:  2015-01-06       Impact factor: 56.272

Review 2.  Pulmonary complications of sickle cell disease.

Authors:  Andrew C Miller; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2012-03-23       Impact factor: 21.405

3.  An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.

Authors:  Elizabeth S Klings; Roberto F Machado; Robyn J Barst; Claudia R Morris; Kamal K Mubarak; Victor R Gordeuk; Gregory J Kato; Kenneth I Ataga; J Simon Gibbs; Oswaldo Castro; Erika B Rosenzweig; Namita Sood; Lewis Hsu; Kevin C Wilson; Marilyn J Telen; Laura M Decastro; Lakshmanan Krishnamurti; Martin H Steinberg; David B Badesch; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2014-03-15       Impact factor: 21.405

4.  Severe sickle cell anemia is associated with increased plasma levels of TNF-R1 and VCAM-1.

Authors:  Daniel A Dworkis; Elizabeth S Klings; Nadia Solovieff; Guihua Li; Jacqueline N Milton; Stephen W Hartley; Efthymia Melista; Jason Parente; Paola Sebastiani; Martin H Steinberg; Clinton T Baldwin
Journal:  Am J Hematol       Date:  2011-02       Impact factor: 10.047

5.  End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.

Authors:  Ann T Farrell; Julie Panepinto; Ankit A Desai; Adetola A Kassim; Jeffrey Lebensburger; Mark C Walters; Daniel E Bauer; Rae M Blaylark; Donna M DiMichele; Mark T Gladwin; Nancy S Green; Kathryn Hassell; Gregory J Kato; Elizabeth S Klings; Donald B Kohn; Lakshmanan Krishnamurti; Jane Little; Julie Makani; Punam Malik; Patrick T McGann; Caterina Minniti; Claudia R Morris; Isaac Odame; Patricia Ann Oneal; Rosanna Setse; Poornima Sharma; Shalini Shenoy
Journal:  Blood Adv       Date:  2019-12-10

6.  High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension.

Authors:  Nambirajan Sundaram; Anitaben Tailor; Laurel Mendelsohn; Janaka Wansapura; Xunde Wang; Tomoyasu Higashimoto; Michael W Pauciulo; William Gottliebson; Vijay K Kalra; William C Nichols; Gregory J Kato; Punam Malik
Journal:  Blood       Date:  2010-03-24       Impact factor: 22.113

7.  Serum levels of soluble ICAM-1 in children with pulmonary artery hypertension.

Authors:  Melahat Melek Oguz; Ayse Deniz Oguz; Cihat Sanli; Ayhan Cevik
Journal:  Tex Heart Inst J       Date:  2014-04-01

8.  Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice.

Authors:  Paritha I Arumugam; Eric S Mullins; Shiva Kumar Shanmukhappa; Brett P Monia; Anastacia Loberg; Maureen A Shaw; Tilat Rizvi; Janaka Wansapura; Jay L Degen; Punam Malik
Journal:  Blood       Date:  2015-08-18       Impact factor: 22.113

9.  Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions.

Authors:  Gregory J Kato; Robert P Hebbel; Martin H Steinberg; Mark T Gladwin
Journal:  Am J Hematol       Date:  2009-09       Impact factor: 10.047

10.  Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease.

Authors:  Xiaomei Niu; Mehdi Nouraie; Andrew Campbell; Sohail Rana; Caterina P Minniti; Craig Sable; Deepika Darbari; Niti Dham; N Scott Reading; Josef T Prchal; Gregory J Kato; Mark T Gladwin; Oswaldo L Castro; Victor R Gordeuk
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.